STRATA Skin Sciences, Inc. Annual Report: A Plain-English Guide

I have put together this guide to help you understand how STRATA Skin Sciences performed this year. My goal is to break down the company’s filings into simple terms, without the confusing Wall Street jargon.

1. What does this company do?

STRATA is a medical technology company focused on skin conditions like psoriasis, vitiligo, and acne. Their main product is the XTRAC laser system. This laser uses a targeted beam of UVB light to clear skin lesions.

Think of their business like a printer company. Instead of just selling the machine, they place the XTRAC laser in a doctor’s office for no upfront cost. They make money on a "per-use" basis, charging a fee every time a doctor treats a patient. As of December 31, 2025, they have 842 systems installed. They also offer the TheraClearX system for acne and distribute the VTRAC lamp for smaller treatments.

2. Financial performance

The company is not yet profitable. For the year ending December 31, 2025, they lost about $6.3 million on $32.4 million in revenue. Since they started, they have accumulated total losses of about $254.4 million. Their profit margin on products sold was 55.2%, which covers the costs of maintaining the lasers and making treatment tips.

3. Major wins and challenges

• The "Printer" Model: This recurring revenue is their main engine, making up about 80% of total revenue. By keeping 842 systems in offices, they earned $25.9 million in treatment fees this year.
• International Reach: They moved from using outside distributors to a direct-sales model. This helps them keep more profit in markets like China, Japan, and the Middle East.
• Insurance Updates: Starting in 2026, Medicare finalized specific billing codes for excimer laser treatments. This gives doctors a reliable way to get paid for using STRATA’s equipment.

4. Financial health: The "Red Flag"

Investors should be very careful here. STRATA is currently in default on their long-term debt with MidCap Financial. This happened because the company was delisted from the Nasdaq exchange in early 2026, which triggered a technical default on their loan.

The lender now has the right to demand the full $10.5 million loan balance immediately. Because of this, the company included a "going concern" warning. This is a formal note from auditors stating there is significant doubt about the company’s ability to stay in business over the next year without finding more cash or renegotiating their debt.

5. Key risks

• Survival: The company had $4.8 million in cash at year-end. With their current spending and the $10.5 million debt, they face a cash crisis. They will likely need to issue more shares, which would reduce your ownership percentage.
• Supply Chain: XTRAC lasers need high-purity neon gas. Geopolitical instability has made this gas expensive and hard to find, raising the company's costs.
• Stock Status: After being delisted, shares now trade on the OTC (Over-the-Counter) markets. This makes the stock harder to trade and more volatile.
• Competition: STRATA competes with injectable and oral drugs for psoriasis. These drugs are heavily marketed and often more convenient for patients.

6. Future outlook

Management is negotiating with lenders to fix the default, but there is no guarantee of success. Their future depends on keeping their 842 machines running and successfully launching the TheraClearX system. Without new cash or a debt deal, the company faces a high risk of running out of money.

Investor Takeaway: STRATA has a proven "printer" business model that generates steady recurring revenue, but the company is currently in a precarious financial position. The combination of a "going concern" warning, a technical default on debt, and limited cash reserves makes this a high-risk situation. Before considering an investment, weigh the potential of their technology against the very real possibility that the company may need to raise significant capital or restructure its debt to survive the coming year.